Forbes has an interesting article about the pricing, specifically the impact after the introduction of the competing "Auvi-Q" product. The second page goes int

Forbes has an interesting article about the pricing, specifically the impact after the introduction of the competing "Auvi-Q" product. The second page goes into detail about the rebates and discounts given to pharmacy benefit managers which partially explains the list price increases. Article: http://www.forbes.com/sites/matthewherper/2016/08/30/the-consumer-rip-off-at-the-heart-of-the-epipen-scandal/ http://www.forbes.com/sites/matthewherper/2016/08/30/the-con...